Cargando…

Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection

BACKGROUND: Chronic hepatitis C virus (HCV) infection of the liver with either genotype 1 or genotype 3 gives rise to distinct pathologies, and the two viral genotypes respond differently to antiviral therapy. METHODS: To understand these clinical differences, we compared gene transcription profiles...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robinson, Mark W., Aranday‐Cortes, Elihu, Gatherer, Derek, Swann, Rachael, Liefhebber, Jolanda M. P., Filipe, Ana Da Silva, Sigruener, Alex, Barclay, Stephen T., Mills, Peter R., Patel, Arvind H., McLauchlan, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Viral Hepatitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949513/ https://www.ncbi.nlm.nih.gov/pubmed/25800823 http://dx.doi.org/10.1111/liv.12830

Ejemplares similares

Next-Generation Sequencing Sheds Light on the Natural History of Hepatitis C Infection in Patients Who Fail Treatment
por: Abdelrahman, Tamer, et al.
Publicado: (2015)

Global Distribution and Prevalence of Hepatitis C Virus Genotypes
por: Messina, Jane P, et al.
Publicado: (2015)

Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials
por: Brown, Ashley, et al.
Publicado: (2019)

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
por: Hézode, Christophe, et al.
Publicado: (2017)

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies
por: Yao, Betty B., et al.
Publicado: (2020)

A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection
por: Kao, Jia‐Horng, et al.
Publicado: (2016)

Flunarizine prevents hepatitis C virus membrane fusion in a genotype‐dependent manner by targeting the potential fusion peptide within E1
por: Perin, Paula M., et al.
Publicado: (2015)

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)
por: Lawitz, Eric, et al.
Publicado: (2016)

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis
por: Kumada, Hiromitsu, et al.
Publicado: (2015)

High antiviral activity of NS5A inhibitor ABT‐530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection
por: Poordad, Fred, et al.
Publicado: (2016)

Treatment induced clearance of hepatitis E viruses by interferon‐lambda in liver‐humanized mice
por: Sari, Gulce, et al.
Publicado: (2021)

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study
por: Kwo, Paul, et al.
Publicado: (2016)

17,β‐estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle
por: Magri, Andrea, et al.
Publicado: (2016)

Estimating the Net Contribution of Interleukin-28B Variation to Spontaneous Hepatitis C Virus Clearance
por: di Iulio, Julia, et al.
Publicado: (2011)

Histological changes in HCV antibody–positive, HCV RNA–negative subjects suggest persistent virus infection
por: Hoare, Matthew, et al.
Publicado: (2008)

Expression of Paramyxovirus V Proteins Promotes Replication and Spread of Hepatitis C Virus in Cultures of Primary Human Fetal Liver Cells
por: Andrus, Linda, et al.
Publicado: (2011)

Effect of Immune Pressure on Hepatitis C Virus Evolution: Insights From a Single-Source Outbreak
por: Merani, Shahzma, et al.
Publicado: (2011)

Transcriptome Sequencing, Microarray, and Proteomic Analyses Reveal Cellular and Metabolic Impact of Hepatitis C Virus Infection In Vitro
por: Woodhouse, Stephen D, et al.
Publicado: (2010)

IFITM1 is a tight junction protein that inhibits hepatitis C virus entry,
por: Wilkins, Courtney, et al.
Publicado: (2013)

Liver-primed CD8(+) T cells suppress antiviral adaptive immunity through galectin-9-independent T-Cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice
por: Dolina, Joseph S, et al.
Publicado: (2014)

Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States
por: Razavi, Homie, et al.
Publicado: (2013)

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load
por: Gordon, Stuart C, et al.
Publicado: (2013)

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals
por: Martin, Natasha K, et al.
Publicado: (2013)

Paracrine Signals From Liver Sinusoidal Endothelium Regulate Hepatitis C Virus Replication
por: Rowe, Ian A, et al.
Publicado: (2014)

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus
por: van de Ven, Nikolien, et al.
Publicado: (2015)

Branched-chain amino acids reduce hepatic iron accumulation and oxidative stress in hepatitis C virus polyprotein-expressing mice
por: Korenaga, Masaaki, et al.
Publicado: (2015)

DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection
por: Burza, Maria Antonella, et al.
Publicado: (2015)

Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data
por: Wilder, Julius M., et al.
Publicado: (2015)

Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine‐induced neutralizing activity
por: Kachko, Alla, et al.
Publicado: (2015)

Structure-Guided Design Affirms Inhibitors of Hepatitis C Virus p7 as a Viable Class of Antivirals Targeting Virion Release
por: Foster, Toshana L, et al.
Publicado: (2014)

Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C
por: Tsochatzis, Emmanuel A, et al.
Publicado: (2014)

Type I interferon rapidly restricts infectious hepatitis C virus particle genesis
por: Meredith, Luke W, et al.
Publicado: (2014)

Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)
por: Watashi, Koichi, et al.
Publicado: (2014)

Chronic hepatitis C viral infection subverts vaccine‐induced T‐cell immunity in humans
por: Kelly, Christabel, et al.
Publicado: (2016)

Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt
por: Benova, Lenka, et al.
Publicado: (2015)

Hepatitis E virus and fulminant hepatitis–a virus or host-specific pathology?
por: Smith, Donald B, et al.
Publicado: (2015)

Activated Macrophages Promote Hepatitis C Virus Entry in a Tumor Necrosis Factor-Dependent Manner
por: Fletcher, Nicola F, et al.
Publicado: (2014)

Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection
por: Lattimore, Sam, et al.
Publicado: (2014)

Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients
por: Yamasaki, Kazumi, et al.
Publicado: (2014)

Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice
por: Zhang, Hua, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_34fvqrskj9rt8sivi91c89k1m2